At a glance
Before we delve deeper into this question, it is essential to recognise that weight loss for each individual can vary substantially. Each of us reacts to medicines such as Mounjaro differently, and this is compounded by our unique body fat composition, which is further influenced by our diet and exercise habits.
The landmark trial for tirzepatide (Mounjaro) was known as the SURPASS-2 trial, a direct head-to-head comparison with another drug in the glucagon-like peptide 1 (GLP-1) class: semaglutide (Wegovy).
One key research aim of this trial was to evaluate whether Tirzepatide had a positive outcome on glycated haemoglobin in diabetic patients. The results were published in the New England Journal of Medicine. Tirzepatide was superior to semaglutide at all dose levels (5 mg, 10 mg, and 15 mg) for reducing glycated haemoglobin, a long-term measure of blood glucose control. Compared to semaglutide, patients on tirzepatide also lost more body weight.
After the positive results of the SURPASS-2 trial, another randomised control trial (SURMOUNT-1) was conducted a year later and published in the same journal. This time, the key research outcome was obesity.
The trial was a double-blinded, Phase 3 study with 2,539 patients; once-weekly tirzepatide was compared to a placebo for 72 weeks, including a 20-week dose-escalation period.
Key results from the SURMOUNT-1 trial:
Results clearly show that tirzepatide leads to greater weight loss than the placebo, regardless of the dose.
The amount of weight you lose in a month depends on what stage and dose of treatment you are on.
Mounjaro is taken once weekly. To minimise side effects, the current dose should be taken for at least a month before increasing it. The Summary of Product Characteristics for Mounjaro recommends 5mg, 10mg and 15mg as maintenance doses.
The SURMOUNT-1 trial lasted 72 weeks (roughly 18 months). From the results above, at 72 weeks:
Dose | Weight loss in 72 weeks | Predicted average weight loss every 4 weeks* |
---|---|---|
5mg | -15% | -0.83% |
10mg | -19.5% | -1.08% |
15mg | -20.9% | -1.16% |
From this data, the predicted average weight loss in 4 weeks is calculated by dividing 72 by 18 (every 4 weeks).
For example, if an obese male patient weighed 113 kg, this patient could lose just under or over 1 kg in a month, depending on the dose taken. Note that this is a theoretical assumption induced from the data. In practice, there are many reasons why this figure could vary.
One factor is the dose escalation regime. Here is an example Mounjaro dosage regimen:
The doses differ despite the same treatment duration, hence the weight loss percentage will inevitably vary between the doses. You would expect a higher weight loss percentage with the higher maintenance doses, e.g. 15mg once weekly. However, this can take a few months.
Another factor is the ‘optimal’ dose. The clinical data recommends a maximum of 15mg weekly, which is only achievable after several months of treatment. Compared to someone taking Mounjaro initially for the first month, your percentage weight loss would likely be different if you were on month 6 of treatment, for example.
Mounjaro has shown efficacy in helping individuals lose weight, but it is essential not to rush the results. Increasing the doses too quickly can lead to common side effects such as nausea, constipation and diarrhoea.
Your weight loss journey should also incorporate lifestyle changes; a healthy diet and exercise plan should not be underestimated. Alongside continued Mounjaro use at the recommended doses, you should see a gradual decline in weight over the course of ongoing treatment.
Additional Resources
Mounjaro vs Wegovy: A Comprehensive Comparison
Week-by-week Mounjaro Weight Loss Guide
How To Use Mounjaro Injection Pen
Weight loss injections: Ozempic vs. Mounjaro
How long do Mounjaro side effects last?
Weight loss injections: Foods to avoid while using Mounjaro
How Long Do You Take Mounjaro For Weight Loss?
Sources
NEJM: Tirzepatide versus Semaglutide
NEJM Article: Tirzepatide Once Weekly for the Treatment of Obesity
NEJM Supplementary File: Research Summary
Medicines.org.uk: SmPC for Mounjaro
© 2013 - 2025 Al Muhsineen Limited. All Rights Reserved. Registered Pharmacy: 34 Halliwell Road, Bolton BL1 8RL. Registered Office: 254 First Floor, Shearbrow, Blackburn, England, BB1 8DS